Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates March 5, 2022
First patient dosed with ADG106 + ADG116 combination in Ph 1b/2 trial in solid tumors January 28, 2022
Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked ADC Candidates December 23, 2021
FDA Clears IND for Phase 1b/2 Trial of ADG116 in Combination with Pembrolizumab in Patients with Solid Tumors November 30, 2021
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance ADG106 in Combination with KEYTRUDA August 20, 2021
Adagene Announces Clinical Trial Collaboration With Merck to Advance ADG116 and ADG126 in Combination with KEYTRUDA July 25, 2021
Interim dose-escalation data up to 0.3 mg/kg in Ph 1 clinical of ADG116 in patients with advanced/metastatic solid tumors announced March 30, 2021
Exelixis and Adagene to Develop Novel Masked ADCs with Improved Safety and Efficacy Profiles February 6, 2021
ARC Therapeutics Launched to Develop CDK Inhibitors for the Treatment of Advanced and Resistant Cancers August 6, 2020
TC BioPharm Partners with Trinity College Dublin to Develop V Delta 1 γδ T Cell-based Cancer Treatments February 26, 2019
